Latest news
When a Cardiology Trial ‘Wins’, What Actually Improved?
Cardiovascular trials are increasingly using hierarchical composite endpoints to capture treatment effects across survival, hospitalisation, symptoms and quality of life. The approach can reflect clinical priorities more effectively than conventional time-to-first-event analysis, but a positive win ratio does not necessarily mean fewer deaths or cardiovascular events.
IPM Brief – Issue 1 | The Last Mile Starts Here
Cancer Sequencing Becomes the Operating System of Precision Oncology
Personalised Cancer Vaccines Show Longer-Term Staying Power
Europe: the EU Cardiovascular Health Plan is becoming the “cancer plan” moment for heart disease
A new Lp(a) threshold could reshape cardiovascular risk assessment
The next cardiometabolic battleground is ultra-processed food
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
Oral SERDs Face the Hard Test: Where Do They Actually Fit?
Prostate Cancer Value Starts Counting Cognition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.